Group D: 0.0060 ± 0.0023. Al/Cr group A p < 0.001 vs. B and C; NS vs. D. Figure 1 shows a straight line of linear regression of Al/Cr vs. Al-u: y = 8.25x + 7.0 r = 0.41 p < O.001. The data of our research show that the initial renal insufficiency is a cause for Al accumulation if there is an overexposure. The increased urinary excretion of Al persists do be high even months after interrupting Al pharmacological administration (indirect sign of stores that still release Al? or increased gastroduodenal absorption for alteration of the gastrointestinal barrier? or substances occurring in the diet, promoting Al gastroduodenal absorption? or PTH? or acidemia?) [2] [3] [4] . In addition, the urinary Al/Cr ratio is shown to be a valid indicator of increased Al urinary excretion for values > 0.02 (n.v. appears to be < 0.01). Even in initial renal failure, the Al/Cr ratio increases to 341% as compared to controls, and in advanced renal failure it increases to 398%. Finally, conservative therapy with ketoanalogs normalizes both Al urinary excretion (even the Al-u values are reduced compared to controls) and the Al/Cr urinary ratio in uremic patients. Thirty-six patients (n = 10 in group A, B and C; n = 6 in group D) were given an oral load of Al hydroxide (4 g/die for 7 days). The results are as follows: Al clearance, ml/min: Group A: 4.08 ± 1.84 (+148%); Group B: 2.82 ± 0.77 (-61%); Group C: 1.56 ± 0.85 (-54%); Group D: 0.975 ± 0.07 (+5%). Al Fe, %: Group A: 2.88 ± 1.22 (+ 168%); Group B: 9.26 ± 4.3 (-77%); . The data show that the functional reserve of redidual nephrons in eliminating Al after a pharmacological load is already reduced in initial CRF. This same functional reserve is not modified by an artificial diet. 
